Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of
colorectal cancer liver metastases.

Bart Neyns; Maridi Aerts; Yves Van Nieuwenhove; Christel Fontaine; Lore Decoster; Denis Schallier; J. Van Der Auwera; F De Munck; Frederik Vandenbroucke; Hendrik Everaert; Vanessa Meert; Johan De Mey; Mark De Ridder; Georges Delvaux; Jacques De Greve

Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.

Bart Neyns, Maridi Aerts, Yves Van Nieuwenhove, Christel Fontaine, Lore Decoster, Denis Schallier, J. Van Der Auwera, F De Munck, Frederik Vandenbroucke, Hendrik Everaert, Vanessa Meert, Johan De Mey, Mark De Ridder, Georges Delvaux, Jacques De Greve

Onderzoeksoutput: Article › peer review

14 Citaten (Scopus)

Samenvatting

BACKGROUND: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab
(CET) have interesting activity for the treatment of colorectal cancer liver
metastases (CRC-LM).
PATIENTS AND METHODS: Intravenous CET with HAI oxaliplatin (OXA) or i.v.
Irinotecan (IRI) followed by HAI of infusion of folic acid modulated
5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had
failed at least one line of prior chemotherapy.
RESULTS: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts)
and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt),
abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer
(2 pts) with catheter migration and intestinal bleeding (1 pt), reversible
interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with
arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts
(62%). The median time to progression was 8.7 months (95% confidence interval
8-14 months).
CONCLUSION: Intravenous administration of CET with HAI of chemotherapy is
feasible and has promising activity but is associated with specific toxicity.

Originele taal-2	English
Pagina's (van-tot)	2459-2467
Aantal pagina's	9
Tijdschrift	Anticancer Res
Volume	28
Status	Published - 2008

Citeer dit

Neyns, B., Aerts, M., Van Nieuwenhove, Y., Fontaine, C., Decoster, L., Schallier, D., Van Der Auwera, J., De Munck, F., Vandenbroucke, F., Everaert, H., Meert, V., De Mey, J., De Ridder, M., Delvaux, G., & De Greve, J. (2008). Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. Anticancer Res, 28, 2459-2467.

@article{98ebed9e34a94321b606117b09558334,

title = "Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.",

abstract = "BACKGROUND: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM). PATIENTS AND METHODS: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy. RESULTS: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months). CONCLUSION: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.",

keywords = "cetuximab, colorectal cancer, liver metastases",

author = "Bart Neyns and Maridi Aerts and {Van Nieuwenhove}, Yves and Christel Fontaine and Lore Decoster and Denis Schallier and {Van Der Auwera}, J. and {De Munck}, F and Frederik Vandenbroucke and Hendrik Everaert and Vanessa Meert and {De Mey}, Johan and {De Ridder}, Mark and Georges Delvaux and {De Greve}, Jacques",

year = "2008",

language = "English",

volume = "28",

pages = "2459--2467",

journal = "Anticancer Res",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.

AU - Neyns, Bart

AU - Aerts, Maridi

AU - Van Nieuwenhove, Yves

AU - Fontaine, Christel

AU - Decoster, Lore

AU - Schallier, Denis

AU - Van Der Auwera, J.

AU - De Munck, F

AU - Vandenbroucke, Frederik

AU - Everaert, Hendrik

AU - Meert, Vanessa

AU - De Mey, Johan

AU - De Ridder, Mark

AU - Delvaux, Georges

AU - De Greve, Jacques

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM). PATIENTS AND METHODS: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy. RESULTS: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months). CONCLUSION: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.

AB - BACKGROUND: Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM). PATIENTS AND METHODS: Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy. RESULTS: Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months). CONCLUSION: Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.

KW - cetuximab

KW - colorectal cancer

KW - liver metastases

M3 - Article

SN - 0250-7005

VL - 28

SP - 2459

EP - 2467

JO - Anticancer Res

JF - Anticancer Res

ER -

Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.

Samenvatting

Vingerafdruk

Citeer dit